Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611671 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
A Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- Active
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT05611671: Active Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
NCT05611671 is a Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative that is active but no longer recruiting, run by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). The registered enrollment target is 280 participants, below the 42,256-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611671, a Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative, is active but no longer recruiting, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Primary Outcome
* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical remis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MORF-057
Study Locations (20)
Other
- Blacktown Hospital - Blacktown
- Concord Repatriation General Hospital - Concord
- Royal Brisbane and Women's Hospital - Herston
- Fiona Stanley Hospital - Murdoch
- Mater Adult Hospital Brisbane - South Brisbane
- Order Hospital Linz Ltd. - Hospital of Sisters of Mercy - Linz
- Salzburg Regional Hospital - Salzburg
- Medical University of Vienna - Vienna
- Medical Center "Rusemed" EOOD - Rousse
- University Multiprofile Hospital for Active Treatment "ACIBADEM City Clinic" - Sofia
- Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda - Sofia
- Second Multiprofile Hospital for Active Treatment - Sofia - Sofia
California
- Gastro Care Institute - Lancaster
- TLC Clinical Research Inc. - Los Angeles
Florida
- Innova Clinical Trials - Coral Gables
- Eminat, LLC - Miramar - Miramar
Arizona
- Arizona Digestive Health - Sun City - Sun City
New Jersey
- Robert Wood Johnson University Medical School - New Brunswick
Ohio
- Great Lakes Gastroenterology - Mentor
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)4 total trials
What the registry record for NCT05611671 still lists
NCT05611671 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 42,256-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05611671 names 20 study sites across 7 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05611671 about?
NCT05611671 is a clinical study titled "A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC". This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
What is the current status of trial NCT05611671?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2022-11-21. Estimated completion is 2026-08.
What conditions does trial NCT05611671 study?
This clinical trial studies the following conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative.
What interventions are being tested in trial NCT05611671?
The interventions under investigation include: Placebo (DRUG), MORF-057 (DRUG).
Who is sponsoring clinical trial NCT05611671?
This trial is sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05611671 being conducted?
This trial has 20 study locations across Arizona, California, Florida, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05611671's enrollment target sits among peer trials
280 12th of 48 higher than 37 of 48 other Inflammatory Bowel Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Bowel Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Feasibility Test of Action Planning in Pediatric IBD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI